Biomarkers Consortium

The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making. 

Spotlight

Announcing
A new publication from the Plasma Aβ Project shows that some blood-based tests could be the first step in screening for Alzheimer’s disease.
Plasma Abeta lab
Bone Quality
ANNOUNCING
The FDA approves FNIH biomarker qualification plan for the first surrogate endpoint in osteoporosis clinical trials
Spotlight
The FNIH Biomarkers Consortium launches a project to detect the earliest changes in rare neurodegenerative diseases.
Neurofilament Stock
Announcing
The FNIH Biomarkers Consortium launches a project to investigate new methods of detecting measurable residual disease in patients with acute myeloid leukemia.
MRD in AML Stock
Spotlight
The FNIH announces promising new data for Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)
NIMBLE

Vision

Improving health through meaningful measurements.

Mission 

To create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.